Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical esflurbiprofen with peppermint oil for temporomandibular disorders (ESPO-TMD)
jRCTs061260007Recruiting
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of esflurbiprofen in temporomandibular disorder (TMD). Primary endpoint: Change in temporomandibular joint pain during mastication (VAS). Started Apr 2026; status: recruiting.
02
Drugs
esflurbiprofen
03
Conditions
temporomandibular disorder (TMD)
Beyond the preview
Go deeper on jRCTs061260007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061260007.